US 12,753,221 B2 · Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Abstract

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

Claims18

Dependent claims

A bispecific chimeric antigen receptor (CAR), comprising:

(i) an anti-CD20 antigen-binding region which comprises a light chain variable region (VL1) and a heavy chain variable region (VH1) having amino acid sequences set forth in SEQ ID NO:
4 and SEQ ID NO:
3, respectively;
and
(ii) an anti-CD19 antigen-binding region which comprises a light chain variable region (VL2) and a heavy chain variable region (VH2) having amino acid sequences set forth in SEQ ID NO:
5 and SEQ ID NO:
6, respectively;
wherein VL1 is located at the N-terminus of VH1, and
wherein VH2 is located at the N-terminus of VL2.

6 more elements

Dependencies are inferred from the claim text.

Facts

Application

18/183,681Filed 14 Mar 2023 · continuation

Priority

CN 202010188038.117 Mar 2020

Published

US 2024/0139243 A12 May 2024

Granted

6 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 14/70596
Receptors; Cell surface antigens; Cell surface determinants: molecules with a "CD"-designation not provided for elsewhere
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/4211
Immunoglobulin superfamily: cd19 or b4

Family

Application16/877,069Parent of this continuation · filed 18 May 2020

Application17/475,766Parent of this continuation · filed 15 Sep 2021

US 11,207,349 B2Parent of this continuation · filed 28 Dec 2021

Application17/750,658Parent of this continuation · filed 23 May 2022

US 11,439,665 B2Parent of this continuation · filed 13 Sep 2022

US 2024/0139243 A1Pre-grant publication · published 2 May 2024

US 11,633,430 B2Parent of this continuation

US 11,331,347 B2Related patent

US 2021/0290673 A1Published application

US 2022/0031752 A1Published application

US 2022/0288123 A1Published application

US 12,753,221 B2This patent

From the US filing history. Foreign family members aren’t listed.

Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Life of this patent

Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Life of this patent

Abstract

Claims18